Invention:
This innovation focuses on the potential therapeutic use of Allopregnanolone (ALLO), a natural neurosteroid, to treat hypoxic ischemic (HI) brain injury in premature infants. ALLO, naturally produced in the placenta during brain development, is absent in premature infants, which contributes to the neurological deficits observed in HI cases. The proposed solution involves administering ALLO to enhance brain development, promote cell survival, and reduce neuroinflammation and glutamate excitotoxicity. In preclinical studies using a neonatal mouse model, ALLO treatment showed promising results in protecting brain cells, improving motor function, and restoring cognitive abilities. ALLO treated mice exhibited better neurogenesis, reduced inflammation, and protection against mitochondrial damage, which is crucial for overall brain health. These findings suggest that ALLO has significant potential to decrease the incidence and severity of CP in premature infants by promoting brain repair and minimizing injury from HI.
Background:
Hypoxic ischemic (HI) brain injury in premature infants is a leading cause of cerebral palsy (CP). Each year, 40,000 premature infants suffer from major cognitive deficits, with 7,000 developing CP. Currently, there are no effective therapies that can reverse or reduce the long-term brain damage caused by HI. Existing treatments focus on managing symptoms or reducing secondary complications, but they do not target the root causes of the injury. By administering Allopregnanolone (ALLO), a natural neurosteroid essential for brain development, this approach aims to promote neurogenesis, neuroregeneration, and protect against inflammation and mitochondrial damage, offering a direct method to restore brain function. Mouse model studies of ALLO show potential to develop a promising therapeutic option for preventing or reducing the severity of HI and CP in infants.
Applications:
- Therapeutic for hypoxic ischemic (HI) brain injury in premature infants
- Therapeutic for Cerebral Palsy (CP) in premature infants
- Neurology
- Neonatal care
Advantages:
- Promotes neurogenesis and brain repair, directly addressing brain injury
- Reduces neuroinflammation and excitotoxicity, improving neurological outcomes
- Mouse model study results show promising results for ALLO as a therapeutic
- Addresses a condition with no current effective therapies
